Prostate‐specific antigen follow‐up and management for patients undergoing holmium laser enucleation of the prostate
International Journal of Urology · 2024
DOI: 10.1111/iju.15315 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Shingo Kimura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sendai City Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lasers, Solid-State, Laser Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate who needs a careful postoperative monitoring for prostate cancer (PCa) after holmium laser enucleation of the prostate (HoLEP). We examined characteristics and oncological outcomes of HoLEP‐related PCa.
Methods
Patients who underwent HoLEP during 2002–2017 in a Japanese tertiary center were retrospectively analyzed. Patients were divided into non‐PCa, PCa with HoLEP specimen (PCa‐Ope), and PCa diagnosed during follow‐up (PCa‐Post). Outcomes of all HoLEP‐related PCa were monitored.
Results
Of the total 758, 60 (7.9%) were diagnosed with PCa from resected specimen of HoLEP and 9 (1.2%) were diagnosed postoperatively. Preoperative prostate‐specific antigen (iPSA), postoperative PSA (pPSA), and PSA density were significantly higher in both PCa groups than those in non‐PCa group. While iPSA significantly correlated to prostate volume (PV), pPSA was not associated with PV. A receiver‐operating‐characteristics curve demonstrated that pPSA 1.2 ng/mL achieved the optimal cut‐off (AUC 0.95) for the incidence of PCa‐Post. In addition to the incidence of PCa and iPSA, lower enucleation efficiency (enucleated volume /PV) was significantly associated with pPSA >1.2 ng/mL. Among PCa‐Ope, 51 were Grade Group (GG) ≤2 and 42 were followed‐up with active surveillance, whereas 8 of 9 PCa‐Post were GG ≥3 and 2 progressed to death.
Conclusions
Patients undergoing HoLEP are associated with some risk of potential PCa. While oncological outcomes were favorable among PCa‐Ope, postoperative PSA should be carefully monitored even if not diagnosed with PCa with HoLEP specimen. Enucleation efficiency should be also considered not to misread pPSA value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sendai City Hospital, Sendai, Japan.
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Pathology, Sendai City Hospital, Sendai, Japan.
ORCID-Profile: Shingo Kimura, Hiromichi Katayama, Eiichiro Ohara, Shigeto Ishidoya
Zitieren
APA
Kimura, S., Katayama, H., Ohara, E., Aoki, H., Shibuya, R., Naganuma, H., Ishidoya, S., & Ito, A. (2024). Prostate‐specific antigen follow‐up and management for patients undergoing holmium laser enucleation of the prostate. International Journal of Urology. https://doi.org/10.1111/iju.15315
Vancouver
Kimura S, Katayama H, Ohara E, Aoki H, Shibuya R, Naganuma H, et al. Prostate‐specific antigen follow‐up and management for patients undergoing holmium laser enucleation of the prostate. International Journal of Urology. 2024. doi:10.1111/iju.15315
BibTeX
@article{Kimura2024,
author = {Kimura, Shingo and Katayama, Hiromichi and Ohara, Eiichiro and Aoki, Hiroshi and Shibuya, Rie and Naganuma, Hiroshi and Ishidoya, Shigeto and Ito, Akihiro},
title = {Prostate‐specific antigen follow‐up and management for patients undergoing holmium laser enucleation of the prostate},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15315}
}
EUVIMED